Subcutaneous efalizumab is not effective in the treatment of alopecia areata

Journal of the American Academy of Dermatology

Volumn 58, Issue 3, 2008, Pages 395-402

  Price, Vera H ^a   Hordinsky, Maria K ^b   Olsen, Elise A ^c   Roberts, Janet L ^d   Siegfried, Elaine C ^e   Rafal, Elyse S ^f   Korman, Neil J ^g   Altrabulsi, Basel ^h   Leung, Hoi M ^d   Garovoy, Marvin R ^j   Caro, Ivor ^k   Whiting, David A ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Northwest Dermatology and Research Center ^*  (United States)

^e Central Dermatology   (United States)

^f DermResearchCenter of New York Inc   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁱ BAYLOR HEALTH CARE SYSTEM   (United States)

^j Arriva Pharmaceuticals Inc   (United States)

^k GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EFALIZUMAB; PLACEBO;

ADULT; AGED; ALOPECIA AREATA; ARTICLE; AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; FEVER; HAIR GROWTH; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; STATISTICAL ANALYSIS;

ADULT; ALOPECIA AREATA; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HAIR; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; TREATMENT FAILURE;

EID: 38949195709     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.10.645     Document Type: Article

References (24)

1. Madani S., and Shapiro J. Alopecia areata update. J Am Acad Dermatol 42 (2000) 549-566
2. McDonagh A.J., and Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol 27 (2002) 405-409
3. Safavi K.H., Muller S.A., Suman V.J., Moshell A.N., and Melton III L.J. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 70 (1995) 628-633
4. Hordinsky M.K. Clinical presentations of alopecia areata. Dermatol Ther 14 (2001) 291-296
5. Whiting D.A. Histopathologic features of alopecia areata: a new look. Arch Dermatol 139 (2003) 1555-1559
6. Kalish R.S., and Gilhar A. Alopecia areata: autoimmunity-the evidence is compelling. J Investig Dermatol Symp Proc 8 (2003) 164-167
7. Gilhar A., Landau M., Assy B., Shalaginov R., Serafimovich S., and Kalish R.S. Mediation of alopecia areata by cooperation between CD4+ and CD8+ T lymphocytes: transfer to human scalp explants on Prkdc(scid) mice. Arch Dermatol 138 (2002) 916-922
8. Hordinsky M., and Ericson M. Autoimmunity: alopecia areata. J Investig Dermatol Symp Proc 9 (2004) 73-78
9. Thiedke C.C. Alopecia in women. Am Fam Physician 67 (2003) 1007-1014
10. Price V.H. Therapy of alopecia areata: on the cusp and in the future. J Investig Dermatol Symp Proc 8 (2003) 207-211
11. Freyschmidt-Paul P., Happle R., McElwee K.J., and Hoffmann R. Alopecia areata: treatment of today and tomorrow. J Investig Dermatol Symp Proc 8 (2003) 12-17
12. Bolduc C., and Shapiro J. DPCP for the treatment of alopecia areata. Skin Therapy Lett 5 (2000) 3-4
13. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46 (2002) 1-23
14. Pariser D.M., Gordon K.B., Papp K.A., Leonardi C.L., Kwon P., Compton P.G., et al. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled phase III trials: part I. J Cutan Med Surg 9 (2005) 303-312
15. Genentech. Raptiva (efalizumab). [package insert] (2004), Genentech, Inc, South San Francisco (CA)
16. Morgan M., McCreedy R., Simpson J., and Hay R.J. Dermatology quality of life scales-a measure of the impact of skin diseases. Br J Dermatol 136 (1997) 202-206
17. Olsen E.A., Hordinsky M.K., Price V.H., Roberts J.L., Shapiro J., Canfield D., et al. Alopecia areata investigational assessment guidelines-part II. National Alopecia Areata Foundation. J Am Acad Dermatol 51 (2004) 440-447
18. Kaelin U., Hassan A.S., Braathen L.R., and Yawalkar N. Treatment of alopecia areata partim universalis with efalizumab. J Am Acad Dermatol 55 (2006) 529-532
19. Mortensen D.L., Walicke P.A., Wang X., Kwon P., Kuebler P., Gottlieb A.B., et al. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 45 (2005) 286-298
20. Jullien D., Prinz J.C., Langley R.G., Caro I., Dummer W., Joshi A., et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 208 (2004) 297-306
21. Heffernan M.P., Hurley M.Y., Martin K.S., Smith D.I., and Anadkat M.J. Alefacept for alopecia areata. Arch Dermatol 141 (2005) 1513-1516
22. Abramovits W., and Losornio M. Failure of two TNF-alpha blockers to influence the course of alopecia areata. Skinmed 5 (2006) 177-181
23. Ettefagh L., Nedorost S., and Mirmirani P. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 140 (2004) 1012
24. Posten W., and Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol 141 (2005) 759-760